Egyptian International Pharmaceutical Industries Company
CASE:PHAR Stock Report
Market Cap: ج.م15.5b
Egyptian International Pharmaceutical Industries Future Growth
Future criteria checks 4/6
Egyptian International Pharmaceutical Industries is forecast to grow earnings and revenue by 19.5% and 13.1% per annum respectively.
Key information
19.5%
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth
48.4%
Revenue growth rate
13.1%
Future return on equity
25.90%
Analyst coverage
Low
Last updated
23 Apr 2026
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
CASE:PHAR - Analysts future estimates and past financials data (EGP Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
14,793
2,638
2,175
N/A
1
12/31/2027
13,125
2,150
1,988
2,247
1
12/31/2026
11,245
1,622
1,748
1,973
1
12/31/2025
9,441
1,442
-261
1,094
N/A
9/30/2025
9,296
1,257
-1,458
568
N/A
6/30/2025
8,819
1,137
-1,829
-177
N/A
3/31/2025
8,387
811
-1,894
-340
N/A
12/31/2024
7,591
1,096
-4,121
-1,274
N/A
9/30/2024
7,003
1,163
-3,661
-1,316
N/A
6/30/2024
6,344
1,093
-3,638
-1,064
N/A
3/31/2024
5,742
1,237
-4,003
-699
N/A
12/31/2023
5,232
822
-2,198
92
N/A
9/30/2023
4,949
869
-2,493
-227
N/A
6/30/2023
4,491
848
-2,315
-339
N/A
3/31/2023
4,020
658
-1,268
-316
N/A
12/31/2022
3,955
643
-860
-297
N/A
9/30/2022
3,648
581
-555
73
N/A
6/30/2022
3,595
556
44
515
N/A
3/31/2022
3,551
494
83
534
N/A
12/31/2021
3,409
488
-53
384
N/A
9/30/2021
3,171
472
207
426
N/A
6/30/2021
2,978
461
-263
-77
N/A
3/31/2021
2,901
465
-574
-368
N/A
12/31/2020
2,886
487
-39
165
N/A
9/30/2020
2,969
488
-736
-517
N/A
6/30/2020
3,113
534
-233
-1
N/A
3/31/2020
3,266
641
436
652
N/A
12/31/2019
3,411
671
103
280
N/A
9/30/2019
3,294
731
N/A
675
N/A
6/30/2019
3,126
711
N/A
411
N/A
3/31/2019
2,999
735
N/A
-125
N/A
12/31/2018
2,816
701
N/A
-12
N/A
9/30/2018
2,784
611
N/A
-17
N/A
6/30/2018
2,767
688
N/A
55
N/A
3/31/2018
2,654
714
N/A
156
N/A
12/31/2017
2,527
688
N/A
209
N/A
9/30/2017
2,372
671
N/A
400
N/A
6/30/2017
2,210
642
N/A
395
N/A
3/31/2017
2,079
522
N/A
629
N/A
12/31/2016
1,969
487
N/A
641
N/A
9/30/2016
1,873
466
N/A
548
N/A
6/30/2016
1,793
448
N/A
541
N/A
3/31/2016
1,745
427
N/A
453
N/A
12/31/2015
1,697
393
N/A
403
N/A
9/30/2015
1,682
403
N/A
434
N/A
6/30/2015
1,646
340
N/A
399
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHAR's forecast earnings growth (19.5% per year) is above the savings rate (15.1%).
Earnings vs Market: PHAR's earnings (19.5% per year) are forecast to grow faster than the EG market (14.7% per year).
High Growth Earnings: PHAR's earnings are forecast to grow, but not significantly.
Revenue vs Market: PHAR's revenue (13.1% per year) is forecast to grow faster than the EG market (11.2% per year).
High Growth Revenue: PHAR's revenue (13.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PHAR's Return on Equity is forecast to be high in 3 years time (25.9%)
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/16 23:44
End of Day Share Price
2026/05/14 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Egyptian International Pharmaceutical Industries Company is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.